AZ’ Imfinzi fails in head and neck cancer trial
AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Read More
Tag: MedImmune
US approves AZ’ hairy cell leukaemia drug
AstraZeneca and its biologics R&D arm MedImmune have bagged US approval of Lumoxiti for the treatment of hairy cell leukaemia (HCL), marking the first new treatment option in 20 years.
Read More
AZ signs up for access to Compugen’s pipeline
AstraZeneca’s MedImmune has inked a deal with Israeli group Compugen giving it access to the firm’s experimental bi- and multi-specific antibody products.
Read More
AstraZeneca spins out new firm Viela Bio
AstraZeneca’s biologics research and development arm MedImmune has spun out six molecules from its early-stage inflammation and autoimmunity programmes into new independent biotech Viela Bio.
Read More
AZ’ experimental asthma drug fails in Phase III
An experimental therapy being developed by AstraZeneca and its biologics research and development arm MedImmune has failed to hit key targets in two Phase III trials.
Read More
AstraZeneca’s Imfinzi gets speedy US review for lung cancer
US regulators have accepted an application by AstraZeneca and MedImmune to expand the scope of Imfinzi to include patients with a certain form of lung cancer.
Read More
GamaMabs licences AZ technology for new cancer therapy
French biotech GamaMabs Pharma has licensed technology owned by AstraZeneca’s MedImmune to research and produce a novel antibody-drug conjugate (ADC) to treat cancer.
Read More
AZ and Sanofi link on RSV vaccine
AstraZeneca’s MedImmune is partnering with Sanofi’s vaccines arm Sanofi Pasteur on the development and commercialisation of its experimental monoclonal antibody MEDI8897 for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.
Read More
MedImmune, Abpro create new firm
AstraZeneca’s biologics research and development arm MedImmune and US life sciences group Abpro have spun out a new company to advance development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).
Read More
Allergan picks up AZ’ Crohn’s drug in $1.52bn deal
AstraZeneca’s biologics research and development arm MedImmune has signed over global rights to its experimental Crohn’s disease drug MEDI2070 to Allergan, in a deal potentially worth $1.52 billion.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
